BYOMA Blemish Acne Clearing Cleanser: the grouped list and the dated label

The product page names Blemish Acne Clearing Cleanser and describes a creamy cleanser. BYOMA’s separate acne-line article also names the creamy facial cleanser. The label table identifies BYOMA Acne Clearing Cleanser as a salicylic-acid liquid. These are records of the specific cleanser, not evidence that a leave-on cream or serum was separately examined. Product page, line article and label identity.

The product-version guide keeps names and forms connected to their actual records. Here, creamy is the manufacturer’s texture wording, while cleanser identifies the product role. Neither resolves the physical characteristics of an inspected bottle or establishes that another similarly named BYOMA item shares the same preparation.

The current website groups ingredient names under headings such as carrier, humectant and cleanser. The US label provides a narrative inactive list and an ingredient table. GLUCOMANNAN appears in that table but not in the current grouped website list or the label’s narrative inactive list. The discrepancy belongs in the record rather than being silently repaired. Grouped declaration and label presentations.

These observations do not prove a formulation-change date, defective bottle or recall. They establish a precise question about the applicable version. Combining all entries from the documents would produce a new declaration that none supplies as one complete formula. The actual package or manufacturer clarification is needed to settle an individual item’s ingredient record.

BYOMA describes Clearamide as a patent-pending complex associated with barrier resilience. The product page and line article provide that narrative alongside named ingredients and broader acne-related descriptions. Reporting the story does not verify a patent grant, measure the complex in a bottle or establish its independent contribution to a clinical outcome. Complex description and brand-line context.

The distinction helps prevent a branded name from becoming a substitute for the ingredient record. A complex description and a declared salicylic percentage are different specifications. The percentage guide explains why one identified number cannot establish equivalence between complete products. No assay, preparation recipe or compatibility conclusion is derived from these marketing descriptions.

The product page reports 56% improved hydration and up to 51% stronger barrier in four days. It also lists texture, blemish, redness and barrier-related benefits. Those are attributed manufacturer summaries. The stated numbers do not measure pore contraction, and the broader line article does not supply a product-specific protocol that resolves that difference. Cleanser benefit summary and line discussion.

The acquired product summary does not identify a participant group, comparator or complete measurement method. The advertised period is not a schedule for a reader, and the figures cannot become a probability of personal improvement. They remain descriptions of the claimed endpoints, with full-report and method questions still open.

The fresh page identifies 175 mL and displays $13.99. It also contains sold-out wording and a message that pickup availability could not load. Those interface observations do not establish stock at every seller, a future purchase opportunity or the item that an untested checkout would fulfill. The label separately includes a 175 mL pump-bottle record. Current offer display and package table.

FDA treats quantity as a separate package field. The commercial-term guide explains why the container size cannot be converted into a personal treatment duration. No order, shipping charge or payment was tested, and the price remains attached to the observed record rather than a guaranteed final cost. Quantity context.

The label identifies salicylic acid 2% for acne treatment and includes a warning about greater likelihood of dryness or irritation with another topical acne medicine. The product page’s barrier and soothing language remains a separate manufacturer description. Both can be reported without treating one as proof that the other is irrelevant. Label warning and barrier wording.

AAD discusses dryness and irritation with salicylic-acid acne care more broadly. This context does not establish the cleanser’s comfort for a particular person or prescribe a product combination. A concern about skin response requires a different assessment from checking whether a benefit heading and a warning appear in the same product record. AAD discussion.

The label’s April 2025 update and package table improve identification, but they do not establish which ingredient presentation describes a supplied bottle. FDA notes that labeling can change and that similar names may conceal different active records. The version question therefore should stay explicit until the relevant package or manufacturer information resolves it. Dated labeling, current declaration and FDA label context.

The Naturium review and INKEY List review offer further separately documented products. Their links help readers continue examining records. They do not settle BYOMA’s mismatch, authorize a substitution or rank its barrier claims against another product whose full study was not compared.